University of Waterloo researchers have created a tool that leverages artificial intelligence (AI) to personalize breast cancer treatment. The development of machine learning and artificial intelligence technology in recent years has been a game changer, allowing professionals in various industries to streamline processes and gain results that are more effective without having to hire more workers.
This technology can be especially beneficial in the medical industry, as it allows physicians to analyze extremely large data sets and come up with better and more effective ways of treating patients.
Given that breast cancer is one of the most common types of cancer in the United State. and across the world, researchers were bound to employ AI technology in efforts to improve breast cancer therapies. Researchers from the University of Waterloo used this technology to develop a tool that can allow cancer specialists to determine whether breast cancer patients should receive chemotherapy treatment before undergoing surgery to remove as much of the tumor as possible.
While chemotherapy has proven to be effective at killing cancer cells, its side effects are often so severe that patients have to take additional medication to bear the treatment. With this new algorithm, physicians will be able to determine whether opting for chemotherapy first or going straight to surgery is the best option for the patient. The AI tool will spare some patients from the debilitating side effects of chemotherapy, while allowing the patients who could benefit from chemotherapy treatment to receive it.
The algorithm is part of Cancer-Net, an open-source, information-sharing initiative led by University of Waterloo professor of systems design engineering Dr. Alexander Wong. Wong stated it is currently difficult to decide the correct breast cancer treatment for a given patient, adding that it was important to avoid unwanted side effects from a treatment that may not benefit the patient in any real way.
He explained that an AI system capable of predicting whether a breast cancer patient will respond well to treatment provides physicians with a crucial tool that allows them to come up with personalized treatment plans for every patient. Wong, who also acts as the director of the Canada Research Chair in Artificial Intelligence and Medical Imaging and the Vision and Image Processing (VIP) Lab, noted that he was optimistic about the AI tool, as the machine learning technology it uses is capable of discovering patterns and determining whether a breast cancer patient will benefit from specific treatments.
He highlighted that such a tool would help to improve disease recovery and survival.
With so many enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) devoting research resources to different kinds of cancer, a time is coming when patients will stand a better chance of beating the different malignancies afflicting them.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
